March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome

Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine truncations, frame shifts and point mutations in the chemokine receptor CXCR4 have been identified in WHIM syndrome Here, we report on a new WHIM syndrome mutation that results in a frame shift within the codon for Ser339 S339fs5) and compare the properties of S339fs5 with wild type CXCR4 and a previously identified WHIM syndrome Taken together, these studies identify a new WHIM syndrome mutant, CXCR4-S339fs5, that promotes enhanced

August 2022 "The X-linked form of Kallmann syndrome (KS), characterized by hypogonadotropic hypogonadism

G-protein-coupled receptor , GPCR , Group 2 innate lymphoid cell , HES , High-affinity Fc receptor for IgE , Hypereosinophilic syndrome , IFNG-AS1 , IFNγ , IL , IL-13R , IL-13Rα1/2 , IL-1RαP , IL-31R , IL-31RA , IL-33R , IL-4Rα

WHIM syndrome) and in the innate control of the life cycle of papillomavirus, which are commensal inhabiting

SCI leads to severe secondary immunosuppression, called SCI-induced immunodeficiency syndrome (SCI-IDS Hypothalamo-pituitary-adrenal axis , Neuroendocrine immunomodulatory axis , Neuroinflammation , SCI-induced immunodeficiency syndrome